Could a simple blood test boost colon cancer screening in appalachia?
NCT ID NCT06119425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether offering a blood test for colorectal cancer screening would be accepted by average-risk patients in Appalachian outpatient clinics. Over 200 participants were given the option of a standard screening method or a blood-based test called Shield. The goal was to see if the blood test improved screening rates and patient willingness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- blood-based colorectal cancer screening test (Shield by Guardant Health)
- What this could lead to
- If successful, this could show that a simple blood test makes colorectal cancer screening more acceptable and accessible, potentially increasing early detection in underserved areas.
- What could go wrong
- This is a small, completed implementation study, not a trial proving the test's accuracy or impact on cancer outcomes. Results may not apply to other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
231 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 84 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 45-84 years of age (inclusive) * Considered by health-care providers to be "average risk" for CRC as determined by USPSTF guidelines * If a patient opts for blood-based test, they are able and willing to provide blood samples per protocol * Ability to understand and the willingness to participate in the study Exclusion Criteria: * Patients with a personal history of CRC * Patients with a known high-risk family history of CRC precluding the patient from being average risk * Patients with known diagnosis of inflammatory bowel disease or history of polyps * Patients who are currently symptomatic for CRC such as: blood in the stool * Patients with any known medical condition which, in the opinion of the investigator, should preclude enrollment into the study * Have a recorded up to date CRC screening * Patients with a previous abnormal colonoscopy finding who are due for surveillance.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer colon are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johnson City Medical Center
Johnson City, Tennessee, 37604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.